PRESS RELEASE published on 02/10/2026 at 07:30, 1 month 6 days ago Inside Information / Other news releases 15-20 National Hospital and GenSight Biologics treat first patient in GS010/LUMEVOQ® REVISE Study, for Leber Hereditary Optic Neuropathy. Clinical study supported by ANSM and aiming to enroll 14 patients in France GenSight Biologics LHON GS010/LUMEVOQ REVISE Study 15-20 National Hospital
BRIEF published on 01/29/2026 at 00:26, 1 month 18 days ago GenSight Biologics Reports EGM Results Shareholders Capital Increase Extraordinary General Meeting GenSight Biologics Financial Authorizations
PRESS RELEASE published on 01/29/2026 at 00:21, 1 month 18 days ago Inside Information / Other news releases GenSight Biologics announces successful Extraordinary General Meeting approving financial authorizations renewal and clarifying rejection of 8th resolution, enhancing company's strategic flexibility Strategy Extraordinary General Meeting GenSight Biologics Gene Therapies Financial Authorizations
BRIEF published on 12/29/2025 at 08:05, 2 months 18 days ago GenSight Biologics Completes €2.9 Million Fundraising Shareholders Fundraising Gene Therapy Retinal Diseases Compassionate Use
PRESS RELEASE published on 12/29/2025 at 08:00, 2 months 18 days ago Inside Information / Other news releases GenSight Biologics successfully raises nearly €2.9 million to fund gene therapies for retinal neurodegenerative diseases, plans to use proceeds for development and operational needs through 2026 Fundraising Proceeds GenSight Biologics Gene Therapies Retinal Diseases
BRIEF published on 12/22/2025 at 07:05, 2 months 25 days ago Issuance of a compassionate access authorization for GS010/LUMEVOQ® Gene Therapy GenSight Biologics NOHL ANSM Compassionate Access
BRIEF published on 12/22/2025 at 07:05, 2 months 25 days ago GenSight Biologics Receives Compassionate Use Authorization for GS010/LUMEVOQ® in France Gene Therapy Rare Diseases Compassionate Use LHON Treatment ANSM Approval
PRESS RELEASE published on 12/22/2025 at 07:00, 2 months 25 days ago Inside Information / Other news releases GenSight Biologics receives Compassionate Use Authorization in France for GS010/LUMEVOQ® gene therapy indicated for ND4-LHON treatment France GenSight Biologics GS010/LUMEVOQ® Compassionate Use Authorization ND4-LHON
BRIEF published on 11/13/2025 at 18:02, 4 months 2 days ago Heights Capital Management crosses thresholds Convertible Bonds Crossing Thresholds Shares And Voting Rights GenSight Biologics Heights Capital
BRIEF published on 10/30/2025 at 07:35, 4 months 17 days ago GenSight Biologics: Green light for compassionate treatment in the United States FDA GenSight Biologics NOHL Compassionate Access GS010/LUMEVOQ®
Published on 03/15/2026 at 23:25, 11 hours 13 minutes ago Tunkillia 'Phase 2' Resource Upgrade Drilling Begins
Published on 03/15/2026 at 18:00, 16 hours 38 minutes ago SEG Announced 2025 Annual Results Initiating First Special Dividend Distribution Payout Ratio Reached 88% Newly Signed Orders Exceeded RMB100-Billion Mark for the Second Consecutive Year
Published on 03/13/2026 at 23:00, 2 days 11 hours ago CORRECTION FROM SOURCE: EV Nickel Announces Maiden Mineral Resource Estimate for Gemini North Nickel Zone
Published on 03/13/2026 at 23:00, 2 days 11 hours ago Redwood AI Announces Platform Name Change and Appointment of Dr. Mark Dybul as Public Safety & Defense Advisor
Published on 03/13/2026 at 21:30, 2 days 13 hours ago Alset AI Announces Closing of Shares for Debt Transaction
Published on 03/16/2026 at 10:20, 18 minutes ago EightSix Launches Brand Studio: The World's First Brand Music Intelligence System
Published on 03/16/2026 at 10:15, 23 minutes ago NVision and Aarhus University Awarded Innovation Fund Denmark Grant to Advance Clinical Translation of Quantum-Enhanced MRI
Published on 03/16/2026 at 10:05, 33 minutes ago AliExpress Anniversary Sale Hits up to 90% Off as Brand+ Channel Surges with Exclusive Tech Debuts and Price Guarantee
Published on 03/16/2026 at 10:00, 38 minutes ago REPLOID launches crowdfinancing campaign on Invesdor
Published on 03/16/2026 at 09:59, 39 minutes ago EQS-Adhoc: IBU-tec advanced materials AG publishes planning: Revenue expectation of at least EUR 120-140 million in 2030 and EUR 37- 39 million for 2026
Published on 03/16/2026 at 08:30, 2 hours 8 minutes ago CDA - Update on CDA' parks solarization program
Published on 03/13/2026 at 19:50, 2 days 14 hours ago Availability of ENGIE’S 2025 Universal Registration Document
Published on 03/13/2026 at 18:05, 2 days 16 hours ago Availability of the 2025 Universal Registration Document of OPmobility SE
Published on 03/13/2026 at 07:30, 3 days 3 hours ago BIOPHYTIS PRESENTS ITS DEVELOPMENT PROGRAMS IN OBESITY AND SARCOPENIA AT THE ICFSR CONFERENCE
Published on 03/12/2026 at 18:00, 3 days 16 hours ago NEW OR RENEWED AGREEMENTS BETWEEN EURAZEO AND CERTAIN FAMILY SHAREHOLDERS
